Pfizer Allegedly Pressured UNICEF to Keep Secret, Pricing for Anti-Viral Treatment Paxlovid. UNICEF Yielded.

Professor Brook Baker ’76, senior policy analyst for Health GAP, tells Geneva Health Filesthat a negative precedent is being set with respect to transparency for public resources spent in procuring COVID-19 therapeutics: “Not only has the world allowed biopharmaceutical companies to maintain monopoly control over the supply, price, and distribution of COVID-19 countermeasures, it has also consistently allowed them to achieve their profiteering under a veil of secrecy.”